🆕A new 3D model is developed to simulate the tumour microenvironment of a type of lymphoma Its ability to recreate the human tumour microenvironment makes it a valuable tool for further exploration of #follicular #lymphoma and other related diseases 👉i.mtr.cool/asbrzukjfd

🏥 ¿Conoces el trabajo en inmunoterapia que se está desarrollando en el Hospital Clínic y el IDIBAPS? Este artículo de Gaceta Médica explica los principales retos y avances en CAR-T, TILs y células dendríticas en nuestro centro. gacetamedica.com/investigacion/…

👨‍🔬 Our colleagues Carlos Fernandez de Larrea and Alvaro Urbano-Ispizua, along with others, have published groundbreaking research in Clinical Cancer Research on biomarkers of response to CAR T-cell therapy with ARI-0002h 🧬 Congrats on the great work! clinicbarcelona.org/en/news/biomar…

📢 WE ARE HIRING! We offer a position as a Lab Technician at the “Cellular immunotherapies for cancer” group at IDIBAPS. 🔬 If you have experience in biomedical research, lentivirus and CAR-T cells, we want to hear from you! Full details 👉 clinicbarcelona.org/uploads/media/…

Today, at TLH, we summarise a decade of hard work. We wish to thank all colleagues, patients and relatives, who helped us during this amazing journey. thelancet.com/journals/lanha…

⬇️ Only two days left to apply and join our lab!

📄 We are grateful for the reception of our latest work in Nature Communications 💉 There, we explore how CAR affinity modulates CAR-T cells' sensitivity to PD-1/PD-L1-mediated inhibition. 📽️ Check out the abstract video (in Spanish) and dive into the manuscript: nature.com/articles/s4146…

🏥 Llum verda al CAR-T ARI0002h desenvolupat pel #CLÍNIC-IDIBAPS per a pacients amb mieloma múltiple en recaiguda. ✅ El Comitè de l'AEMPS ha donat el vistiplau per aprovar-lo com a medicament de teràpia avançada de fabricació no industrial. 👉clinicbarcelona.org/ca/noticies/ll…

🏥 Luz verde al CAR-T ARI0002h desarrollado por el #CLÍNIC-IDIBAPS para pacientes con #mielomamúltiple en recaída. ✅ El Comité de AEMPS ha dado el visto bueno para aprobarlo como medicamento de terapia avanzada de fabricación no industrial. 👉 clinicbarcelona.org/noticias/luz-v…

Our colleague Aleix Prat #PrecisionOncology's new Nature Communications study shows how tumor biology impacts Patritumab deruxtecan's efficacy in early breast cancer. Low HER2 and complex genetic signatures correlate with higher drug efficacy 🧬🔬 nature.com/articles/s4146…

🚀🔬 Throwback to the KAIROS-FORTALECE kick-off meeting at IDIBAPS, where the 6 involved research groups and the Patient Advisory Group discussed the key points of the program 💡 ⬇️ Read more: clinicbarcelona.org/en/news/the-in…

🗓️💡 On this day in July 1921 (over 100 years ago!), Canadian surgeon Frederick Banting and University of Toronto (University of Toronto) medical student Charles Best successfully isolated the hormone insulin for the first time, an outstanding achievement for diabetes treatment.

✅ The CAR-T ARI0002h developed by IDIBAPS-Hospital Clínic has been approved for patients with multiple myeloma. It's inspiring to see how academic CAR T cells are now available for patients. Congratulations to the entire team that made this possible! 👏 clinicbarcelona.org/en/news/green-…

📝💉 Great review on CAR T cell combination therapies! Kudos to Ugur Uslu, Sofía Castelli, and Carl June for such a comprehensive work. sciencedirect.com/science/articl…

📢💉 TECELRA® (afamitresgene autoleucel) has become the first engineered cell therapy for a solid tumor cancer approved by the U.S. FDA. 👏 Congratulations to Adaptimmune and everyone involved in achieving this incredible milestone! adaptimmune.com/investors-and-…

Las editoriales científicas disparan los precios y multiplican su facturación Seis de los principales grupos han incrementado el precio medio por publicar artículos un 26,6% en los últimos cuatro años, alcanzando una facturación de un 250% más eldiario.es/1_affa4a

Un nuevo artículo, ahora en elDiario.es que se ocupa de mostrar, negro sobre blanco, los obscenos beneficios de las editoriales de revistas científicas a partir del dinero que tenemos que pagar los investigadores para publicar nuestros resultados. Locura. eldiario.es/sociedad/mejor…

El 2️⃣3️⃣% de los ensayos clínicos autorizados en España en 2023 son para enfermedades raras. Esta y otra información relevante ha sido publicada por la AELMHU en su Informe Anual sobre Ensayos Clínicos en Enfermedades Raras 📋